



Networked Pharma

A new model for drug discovery & development

'Funds & Fundability'

The ecosystem for drug discovery is changing rapidly, as approaches to both financing and accessing innovation evolve. Big Pharma is moving away from discovery research towards out-sourcing and in-licensing innovation whilst traditional VCs are becoming more selective. The result is that a perceived gap is opening in the early stage funding landscape for biotech companies. Funds with "patient capital", including the strategic CVCs, are moving to fulfil the funding need, along with Angels groups, Government initiatives, Research Councils and Charities. Most recently, the dynamic change continues as charity and Big Pharma backed VC funds appear. In parallel new approaches to accessing innovation emerge with discovery-CRO strategic alliances, Open Innovation, crowd sourcing and the embedding of Pharma staff within Universities. Navigation within this system has become complex!

www.networkedpharma.net
info@networkedpharma.net

Join the discussion:



LinkedIn Group:
Networked Pharma



@NWkPharma
#NWkRx



Supported by:



A one-day workshop June 28, 2012

Holiday Inn, Regents Park, London

Who should attend?

Entrepreneurial scientists	Researchers & managers
Tech transfer professionals	in Pharma, Biotechs,
VCs / CVCs	CROs & service providers
IP specialists / lawyers	Funding Bodies

Objectives

- To benchmark & map out the emerging landscape.
- To share best practice.
- To provide actionable findings for both funders & innovators.

Topics will include:

- Current perspectives (pharma, biotech, VC/CVC)
- Patient capital, strategic investing
- Open innovation & crowdsourcing
- Alternative funding models & sources

Confirmed speakers include:

Nigel Pitchford *Imperial Innovations*
David Phillips *SR One*
Andy Richards *serial entrepreneur & business angel*
Hugo Harrod *MVM Life Science Partners LLP*
Julian Gilbert *CEO Acacia Pharma Ltd*
Alison Campbell OBE *Alison Campbell Associates Ltd.*
Ann Mills-Duggan *The Wellcome Trust, SDDI*
John Montana *Argenta*
Chris Beadle *Lilly*
Zahid Latif *Technology Strategy Board*
Ben Sykes *BBSRC*
Sue Dunkerton *HealthTech and Medicines KTN*

Programme & Registration: see reverse

Networking & Trade Exhibition

A3 Poster Pitch Session

For Academics, Biotechs, etc. who have a project they are trying to fund so that funders can rapidly scan to see if they are of potential interest.

Organising team:

BioSpring Ltd



ikoninformatix



Workshop Programme*

Each session will consist of a series of short talks followed by round-table and panel discussions. Start time 08.30, finish at 17.00 followed by a Networking Reception.

Session 1: Where are we today?

The evolving commercial ecosystem of early-stage VCs & innovation providers. Is there a "funding gap"? Where? Who is and will fund what?

Is there really a gap?

Andy Richards, Serial Entrepreneur

Finding value

Hugo Harrod, MVM Life Science Partners LLP

Patient Capital

Nigel Pitchford, Imperial Innovations

What makes a fundable investment?

David Phillips, Partner, SR One

Biotech companies' changing value focus

Julian Gilbert, CEO Acacia Pharma Ltd.

Lunch, Networking Exhibition & Poster Pitches

Session 2: Open Innovation & Crowdsourcing

Emerging innovation sources & approaches to access: Open innovation, Crowdsourcing & Embedding (universities, CROs) - Who's doing it & what's the future?

Open innovation / we're all in it together

Alison Campbell, Chair, PraxisUnico Training Committee

Open Innovation Drug Discovery Portal

Chris Beadle, Open Innovation Drug Discovery., Lilly

The role of the CROs

John Montana, MD, Argenta

Open innovation and the role of Virtual Intermediaries

Jordi Rafols, Innoget

What about IP?

Tim Worden, Partner, Taylor Wessing LLP

Session 3: Alternatives to VC funding

What's out there and for what can it be used?

Overview of non-equity funding sources

Sue Dunkerton, HealthTech and Medicines KTN

Defence (DoD) & Angels

Barbara Domayne-Hayman, former CEO Stabilitech

Research Funding & Industry Interaction Schemes

Ben Sykes, BBSRC

Funding Innovation in the Life Sciences

Zahid Latif, Technology Strategy Board

Wellcome Trust: Seeding Drug Discovery

Ann Mills-Duggan, Wellcome Trust

Registration

Complete the form and return by fax or scan it and email to us.

Fax: **+44 1949 839587**

Email: **registration@networkedpharma.net**

We will send you an invoice; your registration is only provisional until payment has been made. For payment by credit card, please register online at:

www.networkedpharma.com/funding

Registration fees:

Full delegate registration £275 + VAT []

BIA / One Nucleus / Bionow member registration £250 + VAT []

Early bird registration £250 + VAT []

Early bird registrations must be made before May 31, 2012

Poster pitch: £100 + VAT per poster

Poster pitches are only available together with a delegate registration.

Total number of Poster Pitches required: _____

Invoice information

Organisation: _____

Address: _____

City: _____

Postcode _____ Country: _____

Order no: _____

VAT no: _____

Delegate 1

Name: _____

Job title: _____

Email: _____

Delegate 2

Name: _____

Job title: _____

Email: _____

Delegate 3

Name: _____

Job title: _____

Email: _____

Delegate contact information will be given to workshop sponsors / exhibitors. Tick this box if you do NOT agree to this [].

* Programme & speakers may be subject to alteration at the organisers discretion

For further information

Programme or Poster Pitches

E: nick@networkedpharma.net

T: +44 1538 304159

Sponsorship & Exhibition Opportunities

E: stephen@networkedpharma.net

T: +44 1949 839586